Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 15;68(8):1635–1648. doi: 10.2337/db18-1178

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the American Diabetes Association.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

PMC Copyright notice

AGGF1 protein treatment robustly potentiates the therapeutic effects of EPCs on peripheral vascular complications in a hindlimb ischemia model in db/db mice. A hindlimb ischemia model was created in db/db mice. A: Transplantation of AGGF1-pretreated EPCs dramatically improved blood perfusion compared with EPCs without AGGF1 pretreatment in db/db mice. B: Therapeutic effects of AGGF1-pretreated EPCs on necrosis compared with EPCs without AGGF1 pretreatment. C: Therapeutic effects of AGGF1-pretreated EPCs on ambulatory impairment compared with EPCs without AGGF1 pretreatment. D: Effects of AGGF1-pretreated EPCs on the density of CD31⁺ capillary vessels compared with EPCs without AGGF1 pretreatment. *P < 0.05, **P < 0.01. EB, elution buffer; NC, negative control.